InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,804.00
(
0.64%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.57
(
0.00%
)
Bitcoin
57,815.42
(
-0.13%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Bxofscidad

Send PM Follow Ignore
Followers 0
Posts 232
Boards Moderated 0
Alias Born 06/13/2010

Bxofscidad

Re: None

Monday, 12/03/2012 12:52:12 AM

Monday, December 03, 2012 12:52:12 AM

Post# of 80490
Our Next Order of Business


Our next order of business for Ariad is to see what is in the Twenty Eight (28)Ponatinib abstracts that will be reported on at ASH starting next Saturday (12/8) and continuing till 12/11.

Followed shortly thereafter (in my opinion) by the FDA'S approval of Ponatinib's NDA and discovering what the FDA wants to see on the label.

Then we may hear about a new drug candidate (my guess is that it will address resistance and intolerance in Breast Cancer) followed by Ariad's ASCO presentations.


Has anyone heard any anecdotal evidence of 113 working on EGFR? If so, please report same.

Barry
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up